
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 26, 2024**

ADAPT IMMUNE THERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

England and Wales
(State or other jurisdiction of
incorporation)

1-37368
(Commission File Number)

Not Applicable
(IRS Employer Identification No.)

**60 Jubilee Avenue, Milton Park
Abingdon, Oxfordshire OX14 4RX
United Kingdom**
(Address of principal executive offices, including zip code)

(44) 1235 430000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share	ADAP	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 27, 2024 Adaptimmune Therapeutics plc (the “Company”) announced the appointment of Cintia Piccina as Chief Commercial Officer (“CCO”) effective as of March 18, 2024.

On February 26, 2024, Ms. Piccina entered into an employment agreement (the “Employment Agreement”) with the Company’s U.S. subsidiary, Adaptimmune, LLC (the “Employer”). Under the terms of the Employment Agreement, effective March 18, 2024, Ms. Piccina will receive an annual base salary of \$460,000, which may be modified by the Employer in its sole discretion.

In addition to the base salary, Ms. Piccina will be eligible to receive an annual discretionary bonus following the end of each calendar year that ends during her employment period when she serves as CCO (“Annual Bonus”), subject to: (i) objective criteria set forth by the Company’s Board of Directors (the “Board”) or an authorized delegate thereof on an annual basis; and (ii) the overall performance of the Company. The initial target Annual Bonus effective from March 18, 2024 will be forty-five percent of Ms. Piccina’s base salary. The Annual Bonus payment will be pro-rated for any partial year of service.

In addition to the base salary, Ms. Piccina will receive reimbursement of the cost of business expenses for temporary accommodation in the Boston area for a period of six months commencing from a date to be agreed between the Company and Ms. Piccina (the “Transition Business Expenses Period”) at the rate of up to a maximum amount of \$5,000 per month (the “Transition Business Expenses Payments”) with the first such payment to be made no later than the end of November 2024. The Transition Business Expenses Payments will be paid to Ms. Piccina less applicable deductions and withholding required by law. In addition, Ms. Piccina will also receive a one-time payment of \$70,000 for relocation expenses which shall be paid after the Transition Business Expenses Period has ended (the “Relocation Payment”). The Relocation Payment will be paid to Ms. Piccina less applicable deductions and withholding required by law. In the event that Ms. Piccina’s employment is terminated by the Company for Cause (as defined in the Employment Agreement) or by Ms. Piccina if she resigns other than for Good Reason (as defined in the Employment Agreement) on a date that precedes the first anniversary of the commencement of her employment with the Company, Ms. Piccina will be liable to repay the full amount of the Transition Business Expenses Payments and the Relocation Payment. In order to facilitate any such repayment, whether of the Transition Business Expenses Payments or the Relocation Payment, the Company may elect, in its absolute discretion, to make deductions from any amounts due to be paid to Ms. Piccina.

Ms. Piccina will also be eligible to participate in the equity plans sponsored and/or maintained by the Company and its affiliates from time to time, in accordance with the terms of any such plans, at the sole and absolute discretion of the Company and the Board or the remuneration committee. On or around March 18, 2024, or such other date as the Board may determine and subject to the rules of the relevant equity plan and any applicable legal or regulatory requirements, Ms. Piccina will be awarded market value options to acquire ordinary shares in the Company and RSU-style options to acquire ordinary shares in the Company on the condition that, at the time of the award of such share options, Ms. Piccina continues to serve as the Company’s CCO and remains employed by the Company and is not under notice of termination (given or received). A portion of the market value options will vest on the date of grant and the remainder of the options will vest over a period of three years from the date of grant. A portion of the RSU-style options will vest over a period of three months from the date of grant and the remainder of the options will vest over a period of four years from the date of grant. The market value options will have an exercise price per ordinary share of not less than one sixth of the closing trading price of the Company’s American Depositary Shares on the last business day prior to the date of grant, translated from USD to GBP, and the RSU-style options will have an exercise price of £0.001 per ordinary share. Effective from March 18, 2024 or such other date as the Board may determine and subject to the rules of the relevant equity plan and any applicable legal or regulatory requirements, the exercise period for 1,125,648 vested market value options held by Ms. Piccina will be extended to expire on January 30, 2032 (the “Revised Exercise Period”). In the event that Ms. Piccina’s employment is terminated by the Company for Cause or by Ms. Piccina if she resigns other than for Good Reason during the Revised Exercise Period, the Board may decide to shorten the Revised Exercise Period. Ms. Piccina will also be entitled to additional employee benefits.

The Company may terminate Ms. Piccina’s employment with or without Cause and without notice, but Ms. Piccina is required to provide at least 60 days’ advance written notice to the Company in order to terminate her employment. In the event of a termination of employment by the Company without Cause or a resignation by Ms. Piccina for Good Reason, upon a change of control, any portion of share option awards that were granted and unvested as of the date of termination will vest and immediately become exercisable on the date of termination. Ms. Piccina will also be entitled to payments under her Employment Agreement and the Company’s executive severance policy in the event of a termination by the Company without Cause or a resignation by Ms. Piccina for Good Reason without a change of control and upon a change of control. In order to receive severance benefits under the Employment Agreement and policy, Ms. Piccina is required to execute a release of claims in favor of the Company and comply with certain other post-employment covenants set forth in the Employment Agreement. The Employment Agreement also contains non-solicitation and non-competition provisions that apply for a twelve-month period post-employment with the Company as well as standard confidentiality provisions.

Since 2014, Ms. Piccina, age 51, has held senior management roles in public companies in the life sciences sector. Most recently, she has served as Chief Commercial Officer at AlloVir (Nasdaq: ALVR) helping to build the company’s commercialization capabilities and team to support the launch of the company’s first allogeneic multi Viral Specific T-cell (VST) therapy, AlloVir’s anticipated first commercial product. Prior to her time at Adaptimmune from January 2022 to March 2023, Ms. Piccina served as the SVP Commercial Oncology and US General Manager at 2seventy bio (Nasdaq:TSVT) and as the SVP Commercial Oncology and US General Manager at bluebird bio (Nasdaq: BLUE) since April 2020. Before that, Ms. Piccina spent over 20 years at Novartis (SIX: NOVN; NYSE: NVS) from 1997 to April 2020, first in Brazil and subsequently in the United States, where she held a series of roles including serving as Vice-President, Global Oncology Cell and Gene Strategy & Program Management Office. Ms. Piccina holds a Doctorate in Pharmacy and Biochemistry from the University of Sao Paulo, Brazil, and an MBA from the Escola Superior de Propaganda e Marketing, Sao Paulo, Brazil.

There are no family relationships between Ms. Piccina and any director or executive officer of the Company, and the Company has not entered into any transactions with Ms. Piccina that are reportable pursuant to Item 404(a) of Regulation S-K. Except as described above, there are no arrangements or understandings between Ms. Piccina and any other persons pursuant to which she was selected as CCO.

The foregoing summary of the Employment Agreement is qualified in its entirety by reference to the complete text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
10.1	<u>Employment Agreement dated February 26, 2024 by and between Adaptimmune, LLC and Cintia Piccina</u>
99.1	<u>Press release dated February 27, 2024</u>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADAPTIMMUNE THERAPEUTICS PLC

Date: February 27, 2024

By: /s/ Margaret Henry

Name: Margaret Henry

Title: Corporate Secretary

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT (this "Agreement") is made as of February 26, 2024 by and between Adaptimmune, LLC (the "Company"), a limited liability corporation and wholly-owned subsidiary of Adaptimmune Limited, and Cintia Piccina, an individual residing at [****] ("Executive").

WHEREAS the Company and Executive desire to enter into this Agreement to establish and govern the terms and conditions of Executive's employment by the Company;

NOW THEREFORE, in consideration of the promises and mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. Employment. The Company agrees to employ Executive and Executive agrees to provide services to the Company pursuant to this Agreement from March 18, 2024 ("Commencement of Employment") until the termination of Executive's employment hereunder pursuant to Section 5. The period from Commencement of Employment through the date of Executive's termination of employment shall be referred to as the "Employment Period."

2. Position and Duties.

(a) During the Employment Period, Executive shall be employed by the Company and shall serve as the Chief Commercial Officer of Adaptimmune Therapeutics plc (the "PLC") and in such capacity shall have the normal duties, responsibilities, functions and authority of a Chief Commercial Officer, subject to the power and authority of the Chief Executive Officer and the board of directors or the remuneration committee of such board of directors, as applicable (the "Board") of the PLC to expand or limit such duties, responsibilities, functions and authority, and the power and authority of the Board to overrule actions of officers of the Group. During the Employment Period, Executive shall render such services to the Group which are consistent with Executive's position and as the Chief Executive Officer and the Board may from time to time direct.

In this Agreement, "Group" means the PLC and its subsidiaries from time to time and "Group Company" means a company which is a member of the Group and includes the Company.

(b) During the Employment Period, Executive shall report to the Chief Executive Officer and shall devote her best efforts and her full business time and attention to the business and affairs of the Group. Executive shall perform her duties, responsibilities and functions to the best of her abilities in a diligent, trustworthy, professional and efficient manner, shall comply with the policies and procedures of the Company and of the PLC and shall comply with all applicable federal, state and/or local laws. In performing her duties and exercising her authority under this Agreement, Executive shall develop, support and implement the business and strategic plans approved from time to time by the Board. So long as Executive is employed by the Company, Executive shall not, without the prior written consent of the Board, accept other employment or perform other services for compensation, which the Board reasonably considers may be, or become harmful to the interests of the Company or any Group Company or which might reasonably be considered to interfere with Executive's duties under this Agreement. Notwithstanding the foregoing, nothing in this Agreement shall preclude Executive from engaging in educational, charitable, political, professional and civic activities, provided that such engagement does not interfere with Executive's duties and responsibilities hereunder.

(c) During the Employment Period, Executive's primary work location shall be Boston, Massachusetts; provided, however, that Executive shall travel to other locations and countries as and when required by the Board including, but not limited to, travel to the Group's affiliate offices in the United Kingdom.

3. At-Will Relationship. Executive's employment with the Company is at-will and not for any specified period and may be terminated by either Executive or the Company at any time for any or no

reason, subject to Section 5 of this Agreement. Nothing in this Agreement is intended to or should be construed to contradict, modify or alter this at-will employment relationship.

4. Compensation and Benefits.

(a) Base Salary. During the Employment Period, Executive's base salary initially, with effect from March 18, 2024 shall be \$460,000 per annum, which may be modified by the Company in its sole discretion (the "Base Salary"), and which shall be payable by the Company in regular installments in accordance with the Company's payroll practices in effect from time to time, less applicable deductions and withholding as required by law. For the avoidance of doubt, in any partial calendar year in the Employment Period, the Base Salary shall be prorated to reflect the period of time for which Executive is actually employed by the Company pursuant to this Agreement. During the Employment Period, the Base Salary shall be reviewed annually by the Company in accordance with the guidelines and procedures of the Group applicable to similarly situated executives with the first such review effective January 2025.

(b) Annual Bonus. Subject to the terms of the Executive Severance Policy of the PLC, in force from time to time (the "Executive Severance Policy"), in addition to the Base Salary, Executive will be eligible to receive a bonus following the end of each calendar year that ends during the Employment Period ("Annual Bonus"), subject to: (i) objective criteria set forth by the Board or an authorized delegate thereof on an annual basis; and (ii) the overall performance of the Group. The initial target Annual Bonus with effect from March 18, 2024 shall be forty-five percent (45%) of Executive's Base Salary. The Annual Bonus shall be pro-rated for any year of employment and paid in a single lump sum no later than March 15, of the year following the calendar year in which the Annual Bonus, if any, was earned. For clarity, any Annual Bonus payment made to Executive shall be purely discretionary and shall not form part of Executive's contractual compensation under this Agreement. The first review of the target Annual Bonus percentage will occur in January 2025 and thereafter the target Annual Bonus percentage shall be reviewed on an annual basis. If the Company makes an Annual Bonus payment to Executive in respect of a particular calendar year, it shall not be obliged to make subsequent Annual Bonus payments in respect of subsequent calendar years.

Executive must be employed by the Company on December 31st of the calendar year on which the Annual Bonus is based in order to be eligible to receive the Annual Bonus. Any Annual Bonus payments shall be paid to Executive less applicable deductions and withholding as required by law. Nothing in this Agreement will preclude the Board from changing or altering the objective criteria referred to under Section 4(b)(i), in whole or in part, in the Board's sole discretion.

(c) Business Expenses during Transition Period. The Company shall reimburse Executive for the cost of business expenses for temporary accommodation in the Boston area for a period of six months commencing from a date to be agreed between the Company and Executive (the "Transition Business Expenses Period") at the rate of up to a maximum amount of \$5,000 per month (the "Transition Business Expenses Payments") with the first such payment to be made by no later than the end of November 2024. Executive shall claim the Transition Business Expenses Payments by submitting an invoice and/or other documentation that meets the Company's requirements for reclaiming expenses. The Transition Business Expenses Payments shall be paid to Executive less applicable deductions and withholding as required by law.

(d) Relocation assistance. The Company shall make a one-time payment of \$70,000 for relocation expenses which shall be paid after the Transition Business Expenses Period has ended (the "Relocation Payment"). The Relocation Payment shall be paid to Executive less applicable deductions and withholding as required by law.

In the event that the employment under this Agreement is terminated by the Company for Cause or by Executive if Executive resigns other than for Good Reason on a date that precedes the first anniversary of the Commencement of Employment date, Executive agrees that she shall be liable to repay the full (gross) amount of the Transition Business Expenses Payments and the Relocation Payment by no later than the seventh day following the date of termination of the employment under this

Agreement. Executive agrees that in order to facilitate any such repayment, whether of the Transition Business Expenses Payments and/or the Relocation Payment, the Company may elect, in its absolute discretion, to make deductions from any amounts due to be paid to Executive.

For purposes of this Agreement, "Cause" shall mean with respect to Executive one or more of the following: (i) acts or omissions constituting gross negligence, recklessness or willful misconduct on the part of Executive with respect to Executive's obligations or otherwise relating to the business of the Group; (ii) Executive's material breach of the PLC or any Group Company rules, policies and/or procedures; (iii) Executive's material insubordination or material non-performance or willful neglect of assigned duties; (iv) acts or omissions which bring the reputation of the PLC or any Group Company into material disrepute; (v) any act or omission by Executive aiding or abetting a competitor, supplier or customer of the PLC and/or any of its subsidiaries or affiliates to the material disadvantage or detriment of the PLC and/or any of its subsidiaries or affiliates; (vi) Executive's commission of fraud, misappropriation, embezzlement or theft; or (vii) Executive's material breach of this Agreement, including, but not limited to, violation of any of the restrictive covenants set forth in this Agreement.

For purposes of this Agreement, "Good Reason" shall mean that Executive has complied with the "Good Reason Process" (hereinafter defined) following the occurrence of any of the following events: (i) the Company materially reduces the amount of the Base Salary, except for across-the-board salary reductions based on the Group's financial performance similarly affecting all or substantially all senior management employees of each and every Group Company or as otherwise agreed with Executive; (ii) the Company breaches its material obligations under this Agreement, or (iii) the Company materially reduces Executive's authority, duties or responsibilities without Executive's consent. "Good Reason Process" shall mean that: (i) Executive notifies the Company in writing of the first occurrence of one of the Good Reason conditions within sixty (60) days of the first occurrence of such condition; (ii) Executive cooperates in good faith with the Company's efforts, for a period not less than thirty (30) days following such notice (the "Cure Period"), to remedy the condition; (iii) notwithstanding such efforts, the Good Reason condition continues to exist; and (iv) Executive terminates her employment within sixty (60) days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred and no right to terminate for Good Reason shall exist. There is however no obligation on the Company to remedy the condition that is considered by Executive to be Good Reason.

(e) Stock Options. During the Employment Period, Executive shall be eligible to participate in the equity plans sponsored and/or maintained by the Company and its affiliates from time to time, in accordance with the terms of any such plans, at the sole and absolute discretion of the Company and the Board. On or around March 18, 2024 or such other date as the Board may determine and subject to the rules of the relevant equity plan and any applicable legal or regulatory requirements, Executive shall be awarded "market value" options to acquire ordinary shares in the PLC and RSU-style options to acquire ordinary shares in the PLC on condition that, at the time of the award of such stock options, Executive continues to serve as the Chief Commercial Officer of the PLC and remains employed by the Company and is not under notice of termination (given or received). A portion of the market value options shall vest on the date of grant and the remainder of the options shall vest over a period of three years from the date of grant. A portion of the RSU-style options shall vest over a period of three months from the date of grant and the remainder of the options shall vest over a period of four years from the date of grant. The market value options shall have an exercise price per ordinary share of not less than one sixth of the closing trading price of an American Depositary Share on the last business day prior to the date of grant, translated from USD to GBP, and the RSU-style options shall have an exercise price of £0.001 per ordinary share. Effective from March 18, 2024 or such other date as the Board may determine and subject to the rules of the relevant equity plan and any applicable legal or regulatory requirements, the exercise period for 1,125,648 vested market value options held by Executive shall be extended to expire on January 30, 2032 (the "Revised Exercise Period"). In the event that the employment under this Agreement is terminated by the Company for Cause or by Executive if Executive resigns other than for Good Reason during the Revised Exercise Period, the Board may determine that the Revised Exercise Period shall be reduced.

(f) Employee Benefits. During the Employment Period, Executive shall be entitled to participate in all of the Company's then-existing employee benefit programs for which senior executive employees of the Company are generally eligible. Nothing in this Agreement will preclude the Company from changing, altering or terminating any of the plans or programs for which senior executive employees of the Company are eligible, in whole or in part, in the Company's sole discretion.

(g) Vacation. During the Employment Period, Executive shall receive paid vacation per calendar year (prorated to reflect the period of time for which Executive is actually employed by the Company pursuant to this Agreement), to be accrued and taken in accordance with the Company's then-existing vacation policies. In the vacation year in which her employment terminates, Executive's entitlement to vacation shall accrue on a pro-rata basis for each complete month of service during the relevant year. If, on the termination of the employment, Executive has exceeded her accrued vacation entitlement, the excess may be deducted from any sums due to her unless the amounts due to her constitute "deferred compensation" for purposes of Section 409A of the Internal Revenue Code. If Executive has any unused vacation entitlement, the Company may either require Executive to take such unused vacation during any notice period or to accept payment in lieu of vacation. Any payment in lieu of vacation shall only be made in respect of vacation accrued during Executive's final vacation year.

(h) Business Equipment. During the Employment Period, the Company shall provide Executive with equipment for business use in accordance with the Company's then-existing device policy ("Business Equipment"). The Company also agrees to pay reasonable related monthly service charges for the Business Equipment. Executive understands that the Business Equipment provided by the Company is for business use and will remain the property of the Company. Upon termination of employment or on demand by the Company at any time, Executive agrees to immediately return the Business Equipment without copying, deleting or otherwise modifying any data, documents or information stored on the Business Equipment.

5. Notice of Termination

(a) Notice of Termination. Subject to the terms of this Agreement, the Employment Period and Executive's employment with the Company may be terminated by the Company immediately at any time and for any or no reason, and by Executive for any reason including but not limited to Good Reason, on provision of sixty (60) days written notice. Any termination of employment by the Company or by Executive under this Section 5 shall be communicated by a written notice to the other party hereto indicating the specific termination provision in this Agreement relied upon (a "Notice of Termination").

(b) The Executive Severance Policy as in force from time to time shall apply to Executive in relation to the Employment. Such policy may be amended or terminated in accordance with the terms of the policy, save that where any proposed amendment or termination substantially reduces the rights of Executive following the termination of Executive's employment: (i) the Company will consult with Executive on such proposed amendment or termination; and (ii) any such substantial reduction in the rights or benefits of Executive must be agreed with Executive. Where, following consultation, Executive does not agree to any such proposed amendment or termination, then the Executive Severance Policy shall continue in full force and effect without such proposed amendment or termination.

6. Confidential Information

(a) Executive shall not, except as may be required to perform Executive's duties hereunder or as required by applicable law, during the Employment Period and after employment ends (regardless of the reason), without limitation in time or until such information shall have become public other than by Executive's unauthorized disclosure, disclose to others or use, whether directly or indirectly, any non-public confidential or proprietary information with respect to the PLC or any Group Company, including, without limitation, their business relationships, negotiations and past, present and prospective activities, methods of doing business, know-how, trade secrets, data, formulae, product designs and styles, product development plans, customer lists, investors, and all papers, resumes and records (including computer records) of the documents containing such information ("Confidential Information"). Executive stipulates and agrees that as between Executive and the PLC or any Group Company the

foregoing matters are important and that material and confidential proprietary information and trade secrets affect the successful conduct of the businesses of the PLC or any Group Company (and any successor or assignee of the PLC or any Group Company). Nothing about the foregoing shall preclude Executive from testifying truthfully in any forum or from providing truthful information to any government agency or commission.

(b) Executive agrees not to remove from the Company's premises any property of the PLC or any Group Company including, but not limited to, documents, records, or materials containing any Confidential Information, except as necessary to perform Executive's work for the Group.

(c) Executive agrees to deliver or return to the Company, at the Company's request at any time or upon termination of Executive's employment (regardless of the reason): (i) all documents, computer tapes and disks, records, lists, data, drawings, prints, notes and written information (and all copies thereof) furnished by or on behalf of or for the benefit of the PLC or any Group Company or prepared by Executive during the term of Executive's employment by the Company, regardless of whether Confidential Information is contained therein; and (ii) all physical property of the PLC or any Group Company which Executive received in connection with Executive's employment with the Company including, without limitation, credit cards, passes, door and file keys, and computer hardware and software existing in tangible form.

(d) Executive represents and warrants to the Company that Executive took nothing with her which belonged to any former employer when Executive left her prior position and that Executive has nothing that contains any information which belongs to any former employer. If at any time Executive discovers this is incorrect, Executive shall promptly return any such materials to Executive's former employer. The Company does not want any such materials, and Executive shall not be permitted to use or refer to any such materials in the performance of Executive's duties hereunder.

7. Work Product and Intellectual Property, Inventions and Patents.

(a) For purposes of this Agreement, "Work Product" shall include (i) all works, materials, ideas, innovations, inventions, discoveries, techniques, methods, processes, formulae, compositions, developments, improvements, technology, know-how, algorithms, data and data files, computer process systems, computer code, software, databases, hardware configuration information, research and development projects, experiments, trials, assays, lab books, test results, specifications, formats, designs, drawings, blueprints, sketches, artwork, graphics, documents, records, writings, reports, machinery, prototypes, models, sequences, and components; (ii) all tangible and intangible embodiments of the foregoing, of any kind or format whatsoever, including in printed and electronic media; and (iii) all Intellectual Property Rights (as defined below) associated with or related to the foregoing.

"Company Work Product" shall include all Work Product that Executive partially or completely creates, makes, develops, discovers, derives, conceives, reduces to practice, authors, or fixes in a tangible medium of expression, whether solely or jointly with others and whether on or off the Group's premises, in connection with the Group's business (w) while employed by the Company, or (x) with the use of the time, materials, or facilities of the Group, or (y) relating to any product, service, or activity of the Group of which Executive has knowledge, or (z) suggested by or resulting from any work performed by Executive for the Group.

(b) For purposes of this Agreement, "Intellectual Property Rights" means any and all worldwide rights, title, or interest existing now or in the future under patent law, trademark law, copyright law, industrial rights design law, moral rights law, trade secret law, and any and all similar proprietary rights, however denominated, and any and all continuations, continuations-in-part, divisions, renewals, reissue, reexaminations, extensions and/or restorations thereof, now or hereafter in force and effect, including without limitation all patents, patent applications, industrial rights, mask works rights, trademarks, trademark applications, trade names, slogans, logos, service marks and other marks, copyrightable material, copyrights, copyright applications, moral rights, trade secrets, and trade dress.

(c) Executive acknowledges and agrees that all Company Work Product is and shall belong to the Company. Executive shall and hereby does irrevocably assign and transfer to the Company all of Executive's right, title, and interest in and to all Company Work Product, which assignment shall be effective as of the moment of creation of such Company Work Product without requiring any additional actions of the parties.

(d) All copyrightable material included in Company Work Product that qualifies as a "work made for hire" under the U.S. Copyright Act is deemed a "work made for hire" created for and owned exclusively by the Company, and the Company shall be deemed the owner of the copyright and all other Intellectual Property Rights associated therewith.

(e) To the extent any of the rights, title, and interest in and to Company Work Product cannot be assigned by Executive to the Company, Executive hereby grants to the Company a perpetual, exclusive, royalty-free, transferable, assignable, irrevocable, worldwide license (with rights to sublicense through multiple tiers of sublicensees) to practice such non-assignable rights, title, and interest. To the extent any of the rights, title, and interest in and to Company Work Product can neither be assigned nor licensed by Executive to the Company, Executive hereby irrevocably waives and agrees never to assert such non-assignable and non-licensable rights, title, and interest against the Company or its affiliates, or its and their directors, officers, agents, employees, contractors, successors, or assigns. For the avoidance of doubt, this Section 7(e) shall not apply to any Work Product that (i) does not relate, at the time of creation, making, development, discovery, derivation, conception, reduction to practice, authoring, or fixation in a tangible medium of expression of such Work Product, to the Group's business or actual or demonstrably anticipated research, development or business; and (ii) was developed entirely in Executive's own time; and (iii) was developed without use of any of the Group's equipment, supplies, facilities, or trade secret information; and (iv) did not result from any work Executive performed for the Group.

(f) Executive agrees, represents, and warrants that to the extent any Prior Work Product exists relating in any way to the Group's existing business, or demonstrably anticipated research and development or future business, which was created, made, developed, discovered, derived, conceived, reduced to practice, authored, or fixed in a tangible medium of expression by Executive prior to Executive's employment with the Company (collectively, the "Prior Work Product") the Executive shall notify the Company of such Prior Work Product and obtain the Company's prior written consent prior to using in any way the Prior Work Product during the course of the Executive's employment with the Company. Executive agrees, represents, and warrants that Executive has no rights in or to any Work Product related to Executive's employment with the Company, or to the Company and its affiliates generally, other than the Prior Work Product. Executive hereby grants to the Company a perpetual, royalty-free, irrevocable, worldwide, fully paid-up license (with rights to transfer, assign, and sublicense through multiple tiers of sublicensees) to practice all Intellectual Property Rights relating to any Prior Work Product that Executive uses, incorporates, or permits to be incorporated, in any Company Work Product. Notwithstanding the foregoing, Executive will not use, incorporate, or permit to be incorporated, any Prior Work Product in any Company Work Product without the Company's prior written consent.

(g) Executive agrees, during and after Executive's employment, to perform and to assist the Company, its affiliates, and its and their successors, assigns, delegates, nominees, and legal representatives with all acts that the Company deems necessary or desirable to permit and assist the Company in applying for, obtaining, perfecting, protecting, and enforcing the full benefits, enjoyment, rights, and title throughout the world of the Company in and to all Company Work Product, which acts and assistance may include, without limitation, the signing and execution of documents (at no cost to the Company) and assistance or cooperation in the filing, prosecution, registration, and memorialization of assignment of any applicable Intellectual Property Rights; acts pertaining to the enforcement of any applicable Intellectual Property Rights; and acts pertaining to other legal proceedings related to Company Work Product. If the Company is unable for any reason to secure Executive's signature to any document that the Company deems necessary or desirable to permit and assist the Company in applying for, obtaining, perfecting, protecting, and enforcing the full benefits, enjoyment, rights and title throughout the world of the Company in and to all Company Work Product, Executive hereby irrevocably designates and appoints the Company, its officers, and directors as Executive's attorney in fact to sign and execute such

documents in Executive's name, all with the same legal force and effect as if executed by Executive. This designation of power of attorney is a power coupled with an interest and is irrevocable. Executive will not retain any proprietary interest in any Company Work Product and shall not register, file, seek to obtain, or obtain any Intellectual Property Rights covering any Company Work Product in Executive's own name.

(h) Executive agrees to disclose and describe to the Company promptly and in writing to the Company all Company Work Product to which the Company is entitled as provided above. Executive shall deliver all Company Work Product in Executive's possession whenever the Company so requests, and, in any event, prior to or upon Executive's termination of employment. After the Company confirms receipt of Company Work Product, Executive shall delete or destroy all Company Work Product in Executive's possession whenever the Company so requests and at the Company's reasonable direction, without retaining any copies thereof, and, in any event, prior to or upon Executive's termination of employment.

(i) Consistent with Executive's obligations under Section 6, Executive shall hold in the strictest confidence, and will not disclose, furnish or make accessible to any person or entity (directly or indirectly) Company Work Product, except as required in accordance with Executive's duties as an Executive of the Company.

(j) Executive agrees to disclose promptly in writing to the Company all Work Product created, made, developed, discovered, derived, conceived, reduced to practice, authored, or fixed in a tangible medium of expression by Executive for three (3) months after the termination of Executive's employment with the Company, whether or not Executive believes such Work Product is subject to this Agreement, to permit a determination by the Company as to whether or not the Work Product is or should be the property of the Company. Executive recognizes that Work Product or Confidential Information relating to Executive's activities while working for the Company and created, made, developed, discovered, derived, conceived, reduced to practice, authored, or fixed in a tangible medium of expression by Executive, alone or with others, within three (3) months after termination of Executive's employment with the Company, may have been so created, made, developed, discovered, derived, conceived, reduced to practice, authored, or fixed in a tangible medium of expression by Executive in significant part while employed by the Company. Accordingly, Executive agrees that such Work Product and Confidential Information shall be presumed to have been created, made, developed, discovered, derived, conceived, reduced to practice, authored, or fixed in a tangible medium of expression during Executive's employment with the Company and are to be promptly disclosed and assigned to the Company unless and until Executive establishes the contrary by written evidence satisfying a clear and convincing evidence standard of proof.

(k) For the avoidance of doubt, Executive shall not be entitled to any additional or special compensation or reimbursement in fulfilling Executive's obligations under this Section 7, except that the Company, in its sole discretion, may reimburse Executive for any reasonable expenses which Executive may incur on behalf of the Company.

8. Immunity under Defend Trade Secrets Act of 2016.

The Defend Trade Secrets Act of 2016 (the "Act") provides that: (1) An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (A) is made – (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. The Act further provides that: an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual: (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.

9. Non-Competition; Non-Solicitation.

(a) Non-Competition. During the Employment Period and for a period of twelve (12) months thereafter (the "Restricted Period"), Executive shall not, without the prior written consent of the Board, directly or indirectly, whether as owner, consultant, Executive, partner, venturer, agent, through stock ownership, investment of capital, lending of money or property, rendering of services, or otherwise, engage or participate in a Competitive Business operating within the Restricted Area.

As used in this Agreement, the term "Competitive Business" means any firm, company or business organization (including in each case any entity which directly or indirectly controls, is controlled by, or is under common control by any firm, company or business organization) which, controls, provides or owns any clinical program (excluding phase 1 clinical programs) utilizing a Competing Therapy or which is commercializing or controlling (whether directly or indirectly) the commercialization of any Competing Therapy or which has filed for a marketing authorization in relation to any Competing Therapy. As used in this Agreement, the term "Competing Therapy" means any cell therapy that comprises the same type of active component or moiety (either alone or in combination with any other active component) as any cell therapy owned, licensed or controlled by the Company (each a "Company Cell Therapy") and where such Company Cell Therapy has either been commercialized by the Company or any of its licensees within the 12 months preceding termination or expiry of the Employment Period or has been the subject of any clinical program (excluding any phase 1 clinical program) sponsored or controlled by the Company in the 12 months preceding termination or expiry of the Employment Period. By way of non-limiting example, the active component of a TCR T-cell therapy would be the TCR (T-cell receptor). Notwithstanding the foregoing, (A) a cell therapy will not be a Competing Therapy where it only targets or is approved for treatment of indications which are different from those in relation to which a Company Cell Therapy has been approved for use, whether as part of a clinical trial or marketing authorization; and (B) Executive may own up to one percent (1%) of the outstanding stock of a publicly held corporation which constitutes or is affiliated with a Competitive Business.

As used in this Agreement, the term "Restricted Area" means the United States, the United Kingdom and any other country in which the Company or any affiliated company; (i) at any time in the twelve (12) months preceding the termination of the Employment Period, has manufactured for, marketed, sold and/or distributed products or services or conducted clinical trials involving the use of T-cell therapy to treat or diagnose human disease; or (ii) plans to, during the Restricted Period, manufacture for, market, sell and/or distribute products or services or conduct clinical trials involving the use of T-cell therapy to treat or diagnose human disease.

(b) Non-Solicitation of Employees. During the Employment Period and the Restricted Period, Executive shall not, directly or indirectly (through another person, entity or otherwise): (i) solicit, induce or attempt to induce any Restricted Person of the Company or any affiliated company to leave the employ of the Company or any affiliated company, or in any way interfere with the relationship between the Company or any affiliated company and any employee thereof; or (ii) hire any Restricted Person who was employed by the Company or any affiliated company at any time during the six (6) months prior to such person's hiring by Executive.

In this Agreement, "Restricted Person" means anyone employed or engaged either (i) directly by the Company or any affiliated company or (ii) indirectly by the Company or any affiliated company through a contract research organization or contract manufacturing organization, at (i) the level of line management (including associate director, director, vice president, senior vice president) or above or equivalent or (ii) research and development staff, manufacturing staff or equivalent or (iii) key personnel engaged for the provision of services to the Company or any affiliated company, and who was so employed or engaged in the six months prior to the termination of employment. The non-solicitation provisions explicitly cover all forms of oral, written or electronic communication, including, but not limited to, communications by email, regular mail, telephone, fax, instant message and social media platforms whether or not in existence at the date of this Agreement.

(c) Non-Solicitation of Others. During the Employment Period and the Restricted Period, Executive shall not, directly or indirectly (through another person, entity or otherwise): (i) contact, solicit or accept the business of any customer, vendor or client of the Company or affiliated company for any reason except for non-competing purposes unrelated to the use of T-cell therapy to treat or diagnose human disease; or (ii) induce or seek to influence any customer, vendor or client of the Company or affiliated company to discontinue, modify or reduce its business relationship with the Company or affiliated company for any reason.

(d) If, at the time of enforcement of Section 6, 7 or 9 of this Agreement, a court shall hold that the duration, scope or geographical area restrictions stated herein are unreasonable under circumstances then existing, the parties hereto agree that the maximum duration, scope or geographical area reasonable under such circumstances shall be substituted for the stated duration, scope or area and that the court shall be allowed to revise the restrictions contained herein to cover the maximum period, scope and area permitted by law.

(e) Executive acknowledges that Executive's compliance with Sections 6, 7 and 9 of this Agreement is necessary to protect the goodwill, customer relations, trade secrets, confidential information and other proprietary and legitimate business interests of the Company. Executive acknowledges that any breach of any of these covenants will result in irreparable and continuing damage to the Company's business for which there will be no adequate remedy at law and Executive agrees that, in the event of any such breach of the aforesaid covenants, the Company and its successors and assigns shall be entitled to injunctive relief and to such other and further relief as may be available at law or in equity. Accordingly, Executive expressly agrees that upon any breach, or threatened breach, of the terms of this Agreement, the Company shall be entitled as a matter of right, in any court of competent jurisdiction in equity or otherwise to enforce the specific performance of the Executive's obligations under this Agreement, to obtain temporary and permanent injunctive relief without the necessity of proving actual damage to the Company or the inadequacy of a legal remedy, and without posting bond. In the event a court orders the Company to post a bond in order to obtain such injunctive relief for a claim under this Agreement, Executive agrees that the Company will be required to post only a nominal bond. The rights conferred upon the Company in this Section shall not be exclusive of any other rights or remedies that the Company may have at law, in equity or otherwise.

(f) In the event that Executive violates any of the covenants in this Agreement and the Company commences legal action for injunctive or other relief, then the Company shall have the benefit of the full period of the covenants such that the covenants shall have the duration of twelve (12) months computed from the date Executive ceased violation of the covenants, either by order of the court or otherwise. Executive acknowledges that any claim or cause of action of Executive against the Company shall not constitute a defense to the enforcement by the Company of the covenants of Executive in this Agreement. In the event the Company obtains any such injunction, order, decree or other relief, in law or in equity, Executive shall be responsible for reimbursing the Company for all costs associated with obtaining the relief, including reasonable attorneys' fees and expenses and costs of suit.

(g) Executive acknowledges and agrees that the restrictive covenants contained herein (i) are necessary for the reasonable and proper protection of the goodwill of the Company and its trade secrets, proprietary data and confidential information, (ii) are reasonable with respect to length of time, scope and geographic area and (iii) will not prohibit Executive from engaging in other businesses or employment for the purpose of earning a livelihood following the termination of Executive's relationship with the Company.

10. Executive's Representations and Covenants. Executive hereby represents and warrants to the Company that: (i) the execution, delivery and performance of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Executive is a party or by which Executive is bound; (ii) Executive is not a party to or bound by any employment agreement, non-compete agreement or confidentiality agreement with any other person or entity; (iii) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Executive, enforceable in accordance with its terms; and (iv) Executive is authorized to work in the United States

without restriction. Executive hereby acknowledges and represents that she has been made aware of her right to consult with independent legal counsel regarding her rights and obligations under this Agreement and that she fully understands the terms and conditions contained herein. Executive further covenants that she shall not make any statements, other than pursuant to the performance of her job duties and responsibilities, to the press or other media in connection with the Company and/or any affiliated company at any time either during or after the Employment Period without the prior consent of the Chief Executive Officer.

11. Debarment

(a) Executive hereby certifies to the Company that, as provided in Section 306(a) and Section 306(b) of the U.S. Federal Food, Drug and Cosmetic Act (21 U.S.C. SS 335a(a) and 335a(b)) and/or under any equivalent law within or outside the United States, Executive has not in the past been and/or is not currently (or threatened to be or subject to any pending action, suit, claim investigation or administrative proceeding which could result in Executive being) (i) debarred or (ii) excluded from participation in any federally funded healthcare program or (iii) otherwise subject to any governmental sanction in any jurisdiction (including disqualification from participation in clinical research) that would affect or has affected Executive's ability to perform Executive's obligations under this Agreement, or Executive's employment with the Company or prevent Executive from working for the Company in any capacity in any jurisdiction.

(b) Executive hereby confirms that Executive is not on any of the following exclusion lists: (a) Food and Drug Administration Debarment List; (b) General Services Administration Excluded Parties List System; or (c) Office of Inspector General List of Excluded Individuals/Entities. Executive warrants and represents to the Company that Executive will notify the Company immediately if any of the foregoing occurs or is threatened and that the obligation to provide such notice will remain in effect following the termination of Executive's employment with the Company for any reason, voluntary or involuntary. Any violation of this section by Executive may result in the withdrawal of the offer of engagement or the termination of Executive's employment with the Company. Immediately upon the request of the Company at any time, Executive will certify to the Company in writing Executive's compliance with the provisions of this section. Executive hereby confirms that Executive understands that the Company will verify the information Executive certifies under this Agreement. Falsified or incorrect information provided by Executive may result in the withdrawal of the offer of engagement or the termination of Executive's employment with the Company.

12. Survival. Sections 5 through 23, inclusive, shall survive and continue in full force in accordance with their terms notwithstanding the termination of the Employment Period.

13. Notices. Any notice provided for in this Agreement shall be in writing and shall be either personally delivered, sent by reputable overnight courier service or mailed by first class mail, return receipt requested, to the recipient at the address below indicated:

Notices to Executive:

Cintia Piccina

at such address as most currently appears in the records of the Company

Notices to the Company:

Adaptimmune, LLC

351 Rouse Boulevard

The Navy Yard

Philadelphia

PA 19112

Attention: Chief Executive Officer

or such other address or to the attention of such other person as the recipient party shall have specified by prior written notice to the sending party. Any notice under this Agreement shall be deemed to have been given when so delivered, sent or mailed.

14. Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement or any action in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

15. Complete Agreement. This Agreement, those documents expressly referred to herein and other documents of even date herewith embody the complete agreement and understanding among the parties and supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way.

16. No Strict Construction. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party.

17. Counterparts. This Agreement may be executed in separate counterparts (including by means of telecopied signature pages or electronic transmission in portable document format (pdf)), each of which is deemed to be an original and all of which taken together constitute one and the same agreement.

18. Successors and Assigns. This Agreement, including, but not limited to, the terms and conditions in Sections 6, 7 and 9, shall inure to the benefit of, and be binding upon, the heirs, executors, administrators, successors and assigns of the respective parties hereto, but in no event may Executive assign or delegate to any other party Executive's rights, duties or obligations under this Agreement. Executive further hereby consents and agrees that the Company may assign this Agreement (including, but not limited to, Sections 6, 7 and 9) and any of the rights or obligations hereunder to any third party in connection with the sale, merger, consolidation, reorganization, liquidation or transfer, in whole or in part, of the Company's control and/or ownership of its assets or business. In such event, Executive agrees to continue to be bound by the terms of this Agreement.

19. Choice of Law. All issues and questions concerning the construction, validity, enforcement and interpretation of this Agreement and the exhibits and schedules hereto shall be governed by, and construed in accordance with, the laws of the Commonwealth of Pennsylvania, without giving effect to any choice of law or conflict of law rules or provisions (whether of the Commonwealth of Pennsylvania or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the Commonwealth of Pennsylvania.

20. Amendment and Waiver. The provisions of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement (including, without limitation, the Company's right to terminate the Employment Period with or without Cause) shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement.

21. Insurance. The Company may, at its discretion, apply for and procure in its own name and for its own benefit life and/or disability insurance on Executive in any amount or amounts considered advisable. Executive agrees to cooperate in any medical or other examination, supply any information and execute and deliver any applications or other instruments in writing as may be reasonably necessary to obtain and constitute such insurance.

22. Agreement to Arbitrate.

(a) Notwithstanding any express provision to the contrary, Executive and the Company agree that any claim, controversy or dispute between Executive and the Company (including without limitation the Company's affiliates, officers, executives, representatives, or agents) arising out of or

relating to this Agreement, the employment of Executive, the cessation of employment of Executive, or any matter relating to the foregoing shall be submitted to and settled by arbitration before a single arbitrator in a forum of the American Arbitration Association ("AAA") located in Philadelphia, Pennsylvania, and conducted in accordance with the National Rules for the Resolution of Employment Disputes. In such arbitration: (i) the arbitrator shall agree to treat as confidential evidence and other information presented by the parties to the same extent as Confidential Information under this Agreement must be held confidential by Executive; (ii) the arbitrator shall have no authority to amend or modify any of the terms of this Agreement; and (iii) the arbitrator shall have ten (10) business days from the closing statements or submission of post-hearing briefs by the parties to render his/her decision.

(b) All AAA-imposed costs of said arbitration, including the arbitrator's fees, if any, shall be borne by the Company. All legal fees incurred by the parties in connection with such arbitration shall be borne by the party who incurs them, unless applicable statutory authority provides for the award of attorneys' fees to the prevailing party and the arbitrator's decision and award provides for the award of such fees.

(c) Any arbitration award shall be final and binding upon the parties, and any court having jurisdiction may enter a judgment on the award. The foregoing requirement to arbitrate claims, controversies, and disputes applies to all claims or demands by Executive, including without limitation, any rights or claims Executive may have under the Age Discrimination in Employment Act of 1967, Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act of 1991, the Equal Pay Act, the Family and Medical Leave Act or any other federal, state or local laws or regulations pertaining to Executive's employment or the termination of Executive's employment.

(d) All claims must be arbitrated, with the limited exception of claims for violations of Sections 6, 7 or 9 of this Agreement. In the event of an alleged breach of Sections 6, 7 or 9 of this Agreement by Executive, the Company has the option to elect between arbitration and a judicial forum.

23. Corporate Opportunity. During the Employment Period, Executive shall submit to the Company all business, commercial and investment opportunities or offers presented to Executive or of which Executive becomes aware (including in Executive's capacity as agent, employee, director or officer of the Company), irrespective of Executive's evaluation of the reasonableness or desirability of the Company's investigation thereof, which relate to the business of the Company or any of its affiliates or subsidiaries (the "Business") at any time during the Employment Period ("Corporate Opportunities"). Executive acknowledges that all such Corporate Opportunities are for the benefit of the Company and that Executive would be in breach of Executive's duties to the Company if Executive accepted or pursued, directly or indirectly, any such Corporate Opportunity on Executive's own behalf.

As used in this Agreement, the term "Business" means the business of developing, designing, testing, marketing, selling, distributing or manufacturing products or services involving the use of T cell therapy to treat or diagnose human disease and/or any further business that may be developed by the Company or any of its affiliates of which Executive is aware.

24. Executive's Cooperation. During the Employment Period and thereafter, Executive shall reasonably cooperate with the Company and its affiliates or subsidiaries in any internal investigation or administrative, regulatory or judicial proceeding as reasonably requested by the Company (including, without limitation, Executive's being reasonably available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company's reasonable request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are or may come into Executive's possession, all at times and on schedules that are reasonably consistent with Executive's other permitted activities and commitments) at reasonable times. In the event the Company requires Executive's cooperation in accordance with this Section 24, the Company shall reimburse Executive solely for reasonable travel expenses (including lodging and meals, upon submission of receipts). Nothing about the foregoing shall preclude Executive from testifying truthfully in any forum or from providing truthful information to any government agency or commission.

25. 409A Compliance.

(a) The intent of the parties is that payments and benefits under this Agreement comply with Section 409A and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. In no event shall the Company or its subsidiaries or affiliates be liable for any additional tax, interest or penalty that may be imposed on Executive under Section 409A or damages for failing to comply with Section 409A.

(b) A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination is also a "separation from service" within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a "termination," "termination of employment" or like terms shall mean "separation from service."

(c) To the extent that reimbursements or other in-kind benefits under this Agreement constitute "nonqualified deferred compensation" for purposes of Section 409A: (i) all such expenses or other reimbursements hereunder shall be made on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred by Executive; (ii) any such right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit; and (iii) no such reimbursement, expenses eligible for reimbursement, or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year.

(d) For purposes of Section 409A, Executive's right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.

(e) Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes "nonqualified deferred compensation" for purposes of Section 409A be subject to offset by any other amount unless otherwise permitted by Section 409A.

IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.

ADAPTIMMUNE, LLC

By: /s/ Helen Tayton-Martin
Name: Helen Tayton-Martin
Position: President and Secretary

/s/ Cintia Piccina
Cintia Piccina

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

- *Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024*

PHILADELPHIA and OXFORD, UK, February 27, 2024— Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced the reappointment of Cintia Piccina as Chief Commercial Officer effective March 18, 2024. Cintia served in this role from January 2022 to March 2023. Cintia will lead a rapidly expanding commercial team as it prepares for the launch of afami-cel for the treatment of advanced synovial sarcoma which, on approval, will be the first engineered TCR T-cell therapy on the market targeting solid tumors.

Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "It is my pleasure and the Company's great fortune to welcome back Cintia and her wealth of cell therapy commercial expertise. With a priority review and an August 4, 2024 PDUFA date set for afami-cel, we have the opportunity to leverage Cintia's established track record and her familiarity with Adaptimmune, our products, and the company culture. Cintia was instrumental in designing and steering our commercial model design and her leadership will be critical as we continue launch planning and execution for the late-stage products in our sarcoma franchise."

Cintia Piccina, Adaptimmune's incoming Chief Commercial Officer: "I am thrilled to have the opportunity to return to Adaptimmune as we prepare for the launch and commercialization of afami-cel. I look forward to joining this incredible team again as we aim to deliver important and much-needed new treatment options for people diagnosed with advanced cancers."

Most recently, Cintia served as Chief Commercial Officer at AlloVir (NASDAQ: ALVR) helping to build the company's commercialization capabilities and team to support the launch of the first allogeneic multi-Viral Specific T-cell (VST) therapy, AlloVir's anticipated first commercial product. Prior to her time at Adaptimmune, Cintia served as SVP Commercial Oncology and US General Manager at Bluebird Bio (NASDAQ: BLBD)/2seventy Bio (NASDAQ: TSVT), leading the launch of the first cell therapy product in multiple myeloma, Abecma (idecabtagene vicleucel). Before that, she spent more than 20 years at Novartis (SIX:NOVN; NYSE:NVS) from 1997 to April 2020, first in Brazil then in the United States, where she held a series of commercial, marketing, and sales roles across multiple therapeutic areas including oncology. In her final role at Novartis, Cintia was VP, Global Oncology Cell and Gene Strategy & Program Management Office, for Kymriah and the CAR-T pipeline, leading the cross-functional leadership teams for business (marketing, medical affairs, market access), manufacturing, and pipeline. Cintia holds a Doctorate in Pharmacy and Biochemistry from the University of Sao Paulo, Brazil, and an MBA from the Escola Superior de Propaganda e Marketing, Sao Paulo.

On January 31, 2024, Adaptimmune announced that the U.S. Food and Drug Administration (FDA) had accepted for priority review its Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. The application has a PDUFA target action date of August 4, 2024.

About Afami-cel

Afami-cel is an engineered T-cell receptor (TCR) T-cell therapy, targeted to the MAGE A4 cancer target, and designed as a single-dose treatment for advanced synovial sarcoma. The last FDA approved therapy for treatment in this setting was for Votrient in 2012. The BLA submission for afami-cel was supported by clinical data from the SPEARHEAD-1 pivotal trial, which has met its primary endpoint for efficacy. ~39% of patients who received afami-cel had clinical responses with a median duration of response of ~12 months ([CTOS 2022](#)). Median overall survival (mOS) was ~17 months in SPEARHEAD-1 compared to historical mOS of <12 months for people with synovial sarcoma who received two or more prior lines of therapy. Seventy percent of people with advanced synovial sarcoma who respond to afami-cel are alive two years post-treatment.

About Adaptimmune

Adaptimmune is a cell therapy company out to redefine cancer treatment. With personalized medicines that radically improve the patient's experience with the therapy as much as the therapy itself, Adaptimmune is tackling difficult-to-treat solid tumor cancers so that patients and families may experience more unforgettable and important personal moments. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2022, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts

Investor Relations

Juli P. Miller, Ph.D., VP, Corporate Affairs and Investor Relations

T: +1 215 825 9310

M: +1 215 460 8920

Juli.Miller@adaptimmune.com

Media Relations

Dana Lynch, Senior Director of Corporate Communications

M: +1 267 990 1217

Dana.Lynch@adaptimmune.com


